LIANNE KRAEMER HAD BEEN LIVING WITH METASTATIC breast cancer for more than a year when I met her in December 2017 at the Henry B. González Convention Center in San Antonio. Throughout the week, more than 7,000 doctors, scientists, and pharmaceutical- company representatives would descend on the city for the country’s most important breast-cancer conference. Inside the main exhibition hall, it seemed that every major pharmaceutical company was putting on its best come-hither show. A pair of young, lithe dancers whipped flowing fabric through the air at a booth for the drug Faslodex, a new injectable from Astra Zeneca used to treat women with estrogen fueled advanced breast cancer. Novartis had free cupcakes. Tesaro, a company developing new drugs for BRCA- linked breast cancer, had Nutella- branded ice cream cones. Espresso was available at Eli Lilly, and Pfizer had put out small cups of frozen yogurt. Medtronic, a medical- device company, had breasts of raw chicken at its booth so surgeons could test the PlasmaBlade, its new soft-tissue- dissection knife.
Although I had worked as a health-care journalist for nearly a decade, I had never attended this particular conference. I was there to report on the latest scientific advances in breast cancer, but I was also an interested party. Three years earlier, at the age of 35, I had been diagnosed with breast cancer and begun what would be more than a year of treatment. My cancer responded well to the chemotherapy and targeted drug therapy my doctors prescribed, and I was, according to the evidence, cancer-free. I was grateful, but I wanted to learn more about women with metastatic disease whose breast cancer had managed to carry on despite treatment and spread to other parts of their bodies.
Esta historia es de la edición October 14, 2019 de Time.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición October 14, 2019 de Time.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor? Conectar
As employers embrace Al, workers fret-and seek input
THE SWEDISH BUY-NOW-PAY-LATER COMPANY KLARNA has become something of a poster child for the potential benefits of generative artificial intelligence.
Claudia Sheinbaum
A first for Mexico
Afghan women defying the Taliban
WHEN KABUL FELL TO THE TALIBAN, RETURNING Afghanistan to the fundamentalist group's control, women who did not flee faced a reality in which they could no longer be who they are: journalists deleted evidence of their work, artists destroyed their creations, and graduates set fire to their degrees.
The way to a truly restful vacation
TRAVEL CAN DO WONDERS FOR YOUR well-being: expanding your mind, bonding you to loved ones, and connecting you with nature.
SHARING GRIEF AMID WAR
Spring and early summer are difficult times for both Israelis and Palestinians. Israeli Jews move from Passover, the holiday of freedom, to Holocaust Memorial Day, to Memorial Day for Fallen Soldiers and Victims of Terror, to the triumphant celebrations of Independence Day. The days pass with rituals intended to give us a shared meaning as a society and to inculcate and frame Israel's official narrative.
WESTWARD HO, AGAIN
Kevin Costner's risky western epic, Horizon, celebrates the height of the genre without quite getting there itself
DO LESS. IT'S GOOD FOR YOU
Unproductive moments can boost health and happiness
'I don't have faith in doctors anymore!'
How women get pressured into long-term birth control
Strait Talk
TAIWAN'S NEW PRESIDENT LAI CHING-TE IS TAKING A HARD LINE ON CHINA. BEIJING IS NOT AMUSED
How U.S. Commerce Secretary Gina Raimondo is navigating America's AI future
UNTIL MID-2023, ARTIFICIAL INTELLIGENCE was something of a niche topic in Washington, largely confined to small circles of tech-policy wonks.